Potent, non-peptide and orally active oxytocin receptor antagonist (IC50
= 8.9 nM) that displays > 40-fold selectivity over vasopressin V1a
values are 370 and 570 nM respectively). Antagonizes oxytocin-induced uterine contractions in vitro
and in vivo
The technical data provided above is for guidance only. For batch specific data refer to the Certificate of Analysis.
All Tocris products are intended for laboratory research use only.
Attenuation of PGE2α release in ewes infused with the oxytocin antagonist L-368,899.
Mann et al.
Oral oxytocin antagonists.
Discovery and development of a new class of potent, selective, orally active oxytocin receptor antagonist.
Quattropani et al.
1-(((7,7-dimethyl-2(S)-(2(S)-amino-4-(methylsulfonyl)butyramido)bicyclo[2.2.1]-heptan-1(S)-yl)methyl)sulfonyl)-4-(2-methylphenyl)piperazine (L-368,899): an orally bioavailable, non-peptide oxytocin antagonist with potential util
Williams et al.
The citations listed below are publications that use Tocris products. Selected citations for L-368,899 hydrochloride include:
Showing Results 1 - 2 of 2